Chugai establishes Chugai Pharma Korea in South Korea
- Chugai will incorporate Chugai Pharma Korea Co., Ltd. on November 2, 2026 as a 100% owned subsidiary.
- Initial capital is set at 3 billion Korean won (KRW).
- Purpose is to obtain marketing authorization, import and sell pharmaceutical products, and build phased in‑house sales operations in South Korea.
- Planned to commercialize proprietary pipeline assets such as sparsentan, NXT007 and next‑generation macrocyclic peptide drugs after previously relying on local out‑licensing under the Roche alliance.
Strategic move
Chugai has decided to establish a wholly owned local subsidiary, Chugai Pharma Korea Co., Ltd., to create an integrated presence in South Korea spanning regulatory approval through to sales and supply. The company says this step is intended to maximize value from its strengthening proprietary pipeline and increase its contribution to patients in the market.
Rationale and pipeline
South Korea is described as a growth market driven by population aging and policies to improve access to innovative medicines. Chugai cites specific pipeline assets—sparsentan, NXT007 and next‑generation macrocyclic peptide drugs—as reasons to shift from primarily out‑licensing to building in‑house capabilities, while noting the market falls within its Roche strategic alliance territory.
Phased implementation
The firm will expand the subsidiary’s functions and headcount in phases: first to build filing and approval capabilities, then to establish a sales structure toward product launch. The company frames this as a way to maximize product value and drive group growth.
New company details
Planned incorporation date is November 2, 2026. The subsidiary will be fully owned by Chugai, with initial capital of 3 billion KRW, headquartered in Yeoui‑do, Seoul, and led by Representative Director Masaya Seki.
Source: Chugai Pharmaceutical